VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology comp...
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...
Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd , announced that the Company has sign...
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high u...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT...
Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution, announced a license agre...
Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Par...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital...
Corning Incorporated announced a collaboration with the National Institute for Bioprocessing Research and Training (NIBRT), one of the world&rs...
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloi...
Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz P...
ChargePoint Technology, a powder and liquid transfer specialist, has announced the launch of a new robotic material handling solution aimed at increasing s...
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk...
© 2024 Biopharma Boardroom. All Rights Reserved.
